Telbivudine for the Treatment of Chronic Hepatitis B (TA154)

Technology Appraisal Guidance No. 154

Source: National Institute for Health and Care Excellence

1. Guidance

This guidance does not apply to people with chronic hepatitis B who also have hepatitis C, hepatitis D or HIV.

1.1 Telbivudine is not recommended for the treatment of chronic hepatitis B.

1.2 People currently receiving telbivudine should have the option to continue therapy until they and their clinicians consider it appropriate to stop. 

The guidance shown above constitutes Section 1 of the full document. A copy of the full document and a summary of the evidence is available on the Internet at

An abridged version of this guidance (a 'quick reference guide') is also available. Printed copies of the quick reference guide can be obtained by contacting 0845 003 7783 or emailing and quoting reference number N1662. It is also available on the Internet at

This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

© Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.

Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email:

Telbivudine for the Treatment of Chronic Hepatitis B.
Issue Date: August 2008
Review Date: February 2009

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more